X-linked adrenoleukodystrophy (X-ALD) is a debilitating disease caused by mutations in the ABCD1 gene. Approximately 30% of affected boys develop the progressive ...

We expect investors to focus on updates related to Viking Therapeutics’ VKTX pipeline when it reports first-quarter 2025 ...

We also expect the company to provide updates on its NASH and X-ALD drugs, including progress on the collaboration prospects for both drugs. Viking’s earnings performance has been mixed over the ...